Hybio Pharmaceutical Subsidiary Wins NMPA Approval for Chemically Synthesized Liraglutide API

SHENZHEN, China — Hybio Pharmaceutical Co., Ltd. (300199.SZ) announced that its wholly owned subsidiary, Hybio Pharmaceutical (Wuhan) Co., Ltd., has received a Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice from China's National Medical Products Administration for liraglutide.

The approval marks a significant milestone for the Shenzhen-based pharmaceutical company, making it the first enterprise in China to secure regulatory clearance for liraglutide through a chemical synthesis pathway.

Liraglutide is a human glucagon-like peptide-1 analog — or GLP-1 analog — that targets one of the most important drug receptors in modern metabolic medicine. The GLP-1 receptor has drawn intense global pharmaceutical interest in recent years, as drugs acting on this pathway have demonstrated transformative potential in treating obesity and type 2 diabetes.

The drug works through multiple physiological mechanisms: it promotes insulin secretion in a glucose-dependent manner, protects pancreatic beta cells, delays gastric emptying, and reduces appetite. These combined effects have made GLP-1 receptor agonists among the most sought-after therapeutic categories worldwide, with the global market for such drugs valued in the tens of billions of U.S. dollars.

By securing approval for the liraglutide active pharmaceutical ingredient via chemical synthesis, Hybio Pharmaceutical positions itself to supply a key raw material for one of the most commercially significant drug classes in the metabolic disease space. The chemical synthesis route, as opposed to biological fermentation, can offer advantages in production scalability and cost efficiency — factors that could prove critical as demand for GLP-1 therapies continues to surge.

The NMPA approval clears the Wuhan subsidiary to manufacture and supply the liraglutide API for downstream formulation into finished drug products. For Hybio Pharmaceutical, the listing-traded company on the Shenzhen Stock Exchange's ChiNext board, the development represents a concrete step in its strategy to capture value across the pharmaceutical value chain — from raw material production to finished drug development.

The company did not disclose specific financial figures related to the approval in its announcement. Investors and industry observers will be watching for further details on production capacity, pricing, and potential commercial partnerships as Hybio Pharmaceutical moves to capitalize on its first-mover position in China's chemically synthesized liraglutide market.